How Is Synthetic Nicotine Made and Is It Different?

Synthetic nicotine is built from scratch in a chemistry lab, typically starting from petrochemical-derived raw materials rather than being extracted from tobacco leaves. At the molecular level, the end product is the same compound, but the manufacturing route introduces subtle differences in purity profile and, in some cases, the mirror-image orientation of the molecule. Those differences matter more for regulation and testing than for what the nicotine does once it enters your body.

From Petrochemicals to Nicotine in a Few Steps

The most widely documented route to synthetic nicotine begins with ethyl nicotinate, an ester of nicotinic acid (better known as niacin, or vitamin B3). Niacin itself is a bulk industrial chemical produced from petrochemical feedstocks, so at no point does tobacco enter the picture. In a patent assigned to one early manufacturer, ethyl nicotinate is reacted with N-vinyl-2-pyrrolidinone to form myosmine, a compound that also occurs naturally in tobacco. Myosmine is then reduced to nornicotine, and a final methylation step converts nornicotine into nicotine.¹

That basic sequence, ethyl nicotinate → myosmine → nornicotine → nicotine, is the backbone of most commercial synthetic nicotine processes described in patent literature. But the details of each step vary by manufacturer. Some use purely chemical reduction to turn myosmine into nornicotine, achieving yields up to about 90%.² Others rely on a biotechnological shortcut: a commercially available recombinant enzyme (an imine reductase) that converts myosmine directly into the desired form of nornicotine in a single stereoselective step, skipping the need for a separate purification stage.³ The choice of method has a direct bearing on the composition of the final product.

The Mirror-Image Problem

Nicotine exists in two mirror-image forms, called S-nicotine and R-nicotine. They are chemically identical but spatially reversed, like a left hand and a right hand. In tobacco plants, the biosynthetic machinery almost exclusively produces S-nicotine, so tobacco-derived nicotine is typically more than 99% the S form.⁴ S-nicotine is the form your brain’s receptors recognize most readily, the one responsible for the familiar buzz, the reward, and the addictiveness.

A straightforward chemical synthesis, by contrast, produces a 50/50 racemic mixture of both forms.¹ The tobacco industry recognized this issue as far back as the 1960s. Internal documents from British American Tobacco, Reynolds, and Liggett and Myers all concluded that synthetic nicotine’s racemic mixture made it less appealing than tobacco-extracted S-nicotine, and also more expensive to produce.³ The idea was shelved for decades.

Modern manufacturers have solved, or at least partially solved, this problem. One approach is chiral resolution: after producing racemic nicotine, the unwanted R-nicotine is separated out using a chiral acid like L-dibenzoyl tartaric acid that selectively binds one form over the other.³ Another approach uses diastereomeric salts with specialized chiral acids; one recent method reported isolating S-nornicotine at 92% enantiomeric excess before the final methylation step.² The enzymatic route mentioned earlier sidesteps the separation entirely by producing predominantly S-nornicotine from the start. All of these routes aim at the same goal: a finished product that closely matches tobacco-derived nicotine’s nearly pure S-form composition.

Is the Finished Product Actually Identical?

In terms of the nicotine molecule itself, yes. S-nicotine from a lab is the same compound as S-nicotine from a tobacco leaf. Your body cannot tell the difference. But “identical nicotine” does not mean “identical product,” because both sources carry trace impurities, and the impurity profiles diverge.

A 2024 comparison using high-performance liquid chromatography found that total impurities in both synthetic and tobacco-extracted nicotine ran at similar levels, roughly 0.1%. The difference was in what those impurities were. Tobacco-extracted nicotine carried traces of cotinine, nornicotine, and nicotine-N-oxide, compounds naturally present in tobacco. Synthetic nicotine lacked those specific impurities entirely.⁵ Importantly, the synthetic nicotine lots tested in that study also showed high enantiomeric purity comparable to tobacco-derived nicotine, suggesting that modern manufacturers are succeeding at removing the unwanted R-form.

Whether the different impurity profiles matter for health is largely unknown. Cotinine is a well-studied nicotine metabolite and is not considered particularly dangerous on its own; nornicotine and nicotine-N-oxide are present at trace levels in tobacco-extracted nicotine. No study has yet demonstrated a clinically meaningful health difference tied specifically to these trace contaminant variations. What can be said is that the two products are not perfectly interchangeable from an analytical chemistry standpoint, even when the nicotine molecule itself is the same.

How Regulators and Labs Tell Them Apart

If synthetic nicotine is chemically identical to the natural form, how can anyone verify which source a product actually contains? Standard analytical techniques like mass spectrometry and NMR spectroscopy can detect the ratio of S- to R-nicotine, which helps flag racemic products. Researchers confirmed this approach with Puff Bar e-cigarettes: older versions contained only S-nicotine (consistent with tobacco extraction), while newer versions marketed as “tobacco-free” contained both forms, confirming synthetic origin, albeit with a slight excess of the S form.⁴

But that approach has a weakness. As synthetic manufacturers improve their chiral purification, their products increasingly mimic the near-pure S-nicotine profile of tobacco-derived nicotine, making the enantiomer ratio test less definitive. The most reliable method turns out to be radiocarbon analysis. Tobacco plants incorporate carbon-14 from the atmosphere as they grow, so tobacco-derived nicotine shows 100% biobased carbon. Synthetic nicotine, made from petrochemical precursors, contains far less carbon-14 because fossil carbon is essentially radiocarbon-dead. Testing confirmed this cleanly: tobacco-derived samples showed 100% biobased carbon, while synthetic samples returned values around 35–38%.⁶ That small biobased fraction in synthetic samples likely comes from the biological precursor chemicals used partway through the synthesis, but the gap is wide enough to make radiocarbon testing definitive.

What Users Actually Notice

Lab chemistry aside, the question many vapers care about is whether synthetic nicotine feels different. A qualitative study of young adult e-cigarette users found that participants perceived meaningful differences between tobacco-free nicotine (TFN) and tobacco-derived nicotine (TDN) products. Users described TFN e-cigarettes as generally stronger, with a more intense buzz and a different throat hit. Many also reported that TFN products tasted better and felt less harsh.⁷

How much of that difference is pharmacological versus psychological is hard to say. The nicotine molecule is the same, so any real difference in sensation would have to come from the impurity profile, the formulation of the e-liquid (including the choice of acids used to form nicotine salts), or the ratio of S- to R-nicotine. Nicotine salt formulations vary across products regardless of nicotine source; common acids used to create the salt form include benzoic, lactic, levulinic, salicylic, malic, and tartaric acid, each of which can affect smoothness, pH, and perceived throat hit.⁸ A product reformulated as “tobacco-free” might simultaneously have changed its salt formulation, flavoring, or nicotine concentration, any of which could explain the perceived differences as easily as the nicotine source itself.

The Marketing Effect of “Tobacco-Free”

The label “tobacco-free nicotine” is not just a description; it functions as a marketing claim with measurable effects on how people perceive risk. In a randomized experiment, non-tobacco-using young adults who saw a “tobacco-free nicotine” claim on Puff Bar reported higher intentions to use the product, were less likely to view it as very harmful, and were more likely to say they would choose it over other e-cigarettes.⁹

A separate experiment among current e-cigarette users found a similar pattern. Participants exposed to “tobacco-free nicotine” messaging were roughly two-and-a-half times more likely to intend to use TFN products and about two-and-a-half times more willing to pay a premium for them.¹⁰ A third study found that adding “tobacco-free nicotine” language to the FDA’s standard nicotine addiction warning label lowered addictiveness ratings overall. The effect was especially pronounced among younger and racially minoritized participants, who showed disproportionately reduced risk perceptions.¹¹

These findings point to a consistent pattern: the word “tobacco-free” creates a halo effect, making people think the product is less harmful and less addictive, even though synthetic nicotine is pharmacologically the same substance. From a public health standpoint, this is a significant concern because the addictive potential of nicotine does not depend on where it was manufactured.

Nicotine Analogs and the Next Regulatory Gap

The story of synthetic nicotine does not end with nicotine itself. Once the infrastructure exists to build nicotine from scratch, it becomes straightforward to modify the molecule slightly and create novel analogs that may fall outside existing regulations. The most prominent example is 6-methyl nicotine (6MN), a compound where a methyl group is added to nicotine’s pyridine ring.

6MN first appeared in U.S.-marketed e-cigarette products in 2023, advertised as exempt from tobacco regulation. By 2024, it had spread to oral nicotine pouch products sold under brand names like MG and Hippotine, using the trademarked name “Imotine.”¹² The regulatory logic is brazen: because 6MN is not nicotine, the argument goes, products containing it are not “tobacco products” and do not require FDA authorization.

Whether 6MN is actually safer is a different question. Early toxicology data suggests it is not. In laboratory tests on human bronchial cells, e-liquids containing 6MN generated significantly more reactive oxygen species (a marker of oxidative damage) in aerosols than conventional nicotine. 6MN also produced greater cell death and higher intracellular oxidative stress in a dose-dependent manner.¹³ These are cell-culture results, not human health outcomes, but they are enough to demolish any claim that 6MN is a known-safer alternative. The compound is being sold to consumers essentially untested.

Why “Tobacco-Free” Does Not Mean “Risk-Free”

A persistent misconception is that removing tobacco from the equation removes the health risks. Nicotine itself, regardless of origin, constricts blood vessels, raises heart rate and blood pressure, and is highly addictive. The harms that are unique to combustible cigarettes, like tar, carbon monoxide, and thousands of combustion byproducts, are absent from vaping products whether the nicotine is synthetic or plant-derived. But those harms were never caused by the nicotine in the first place; they were caused by burning tobacco leaf. Swapping in synthetic nicotine changes nothing about nicotine’s own cardiovascular and addiction-related effects, and nothing about whatever risks the e-liquid solvents and flavorings themselves pose when heated and inhaled.

For people using nicotine products as a cessation tool, the source of nicotine is largely irrelevant to effectiveness. Nicotine replacement therapies like patches and gum have historically used tobacco-extracted nicotine, and there is no pharmacological reason to expect synthetic nicotine to perform differently in that role. The danger lies in the marketing framing, which can make non-users more willing to start or current users less motivated to quit, as the perception experiments described earlier consistently showed.

How Nicotine Salts Fit into the Picture

Much of the confusion about synthetic nicotine gets tangled up with the separate development of nicotine salt formulations. Freebase nicotine, the form traditionally used in e-liquids, becomes harsh at high concentrations. Pairing nicotine with an organic acid produces a nicotine salt that is smoother to inhale, allowing products to deliver higher nicotine doses without the unpleasant throat burn. The choice of acid matters: benzoic acid is the most widely recognized option (popularized by one major brand), but lactic, levulinic, salicylic, malic, and tartaric acids are also used commercially.⁸

Nicotine salt technology is independent of whether the nicotine is synthetic or tobacco-derived. Both sources can be formulated as freebase or salt. However, because the synthetic nicotine market grew up alongside the nicotine salt trend, consumers sometimes conflate the two. A product labeled “tobacco-free nicotine” is not necessarily a salt formulation, and a salt formulation does not necessarily use synthetic nicotine. When users report that TFN products feel “smoother” or “stronger,” the salt formulation and the acid used are often doing more of the sensory work than the nicotine source itself.

The Cost and Scale Challenge

One reason synthetic nicotine remained a curiosity for decades is cost. Tobacco is an extraordinarily efficient nicotine factory. A hectare of tobacco produces kilograms of nicotine as a natural byproduct of leaf processing, and the extraction is relatively cheap. Synthesizing nicotine from petrochemical starting materials and then purifying it to high enantiomeric purity involves multiple reaction steps, expensive chiral separation agents or enzymes, and careful quality control. For most of the twentieth century, the economics simply did not make sense.

What changed was regulation. When the FDA gained authority over e-cigarettes as “tobacco products,” any nicotine derived from tobacco fell under that regulatory umbrella. Synthetic nicotine, for a time, did not. That regulatory gap created a financial incentive large enough to justify the higher production cost. Companies could sell synthetic nicotine products without submitting premarket tobacco product applications, an enormously expensive and time-consuming process. The U.S. Congress closed much of this loophole in March 2022 by amending the Federal Food, Drug, and Cosmetic Act to include products containing nicotine from any source, not just tobacco. But as the 6-methyl nicotine episode shows, the regulatory game of molecular cat-and-mouse continues with novel analogs that technically are not nicotine at all.

Radiocarbon and the Limits of Self-Reporting

A practical consequence of synthetic nicotine’s existence is the verification problem. Manufacturers self-report the origin of their nicotine, and independent testing is not routine. The radiocarbon method, which cleanly separates fossil-derived carbon from recently-living-plant carbon, is the gold standard for confirmation.⁶ But it requires specialized accelerator mass spectrometry equipment and is not cheap enough for routine product screening. In the Puff Bar analysis, chirality measurements provided a useful first screen, revealing that the “tobacco-free” products indeed contained both nicotine enantiomers.⁴ As manufacturing improves, however, chirality alone will become insufficient, and regulators will need to rely more heavily on radiocarbon or develop new analytical approaches.

For consumers, the bottom line is that there is currently no practical way to independently verify a product’s nicotine source at home. You are trusting the label, and the history of the nicotine industry suggests that label claims deserve healthy skepticism.

1
PubMed Central. Synthetic Nicotine: Science, Global Legal Landscape, and Regulatory Considerations
2
PubMed Central. Efficient Method of (S)-Nicotine Synthesis
3
BMJ Journals. Synthetic nicotine has arrived
4
PubMed Central. Determination of (R)-(+)- and (S)-(-)-Nicotine Chirality in Puff Bar E-Liquids by 1H NMR Spectroscopy, Polarimetry, and Gas Chromatography-Mass Spectrometry
5
Frontiers in Chemistry. Comparison of genotoxic impurities in extracted nicotine vs. synthetic nicotine
6
PLOS ONE. Analysis and differentiation of tobacco-derived and synthetic nicotine products: Addressing an urgent regulatory issue
7
PubMed Central. Why young adults use tobacco-free nicotine E-cigarettes: An analysis of qualitative data
8
PubMed Central. Characterization of Nicotine Salts in Electronic Cigarette Refill Liquids
9
PubMed Central. Effect of a ‘tobacco-free nicotine’ claim on intentions and perceptions of Puff Bar e-cigarette use among non-tobacco-using young adults
10
PubMed Central. Randomised experiment for the effect of ‘Tobacco-Free Nicotine’ messaging on current e-cigarette users’ perceptions, preferences and intentions
11
PubMed Central. Including the term ‘tobacco-free nicotine’ in the nicotine addiction warning label mandated by the US Food and Drug Administration alters risk perceptions and use intentions
12
Tobacco Prevention and Cessation. Introduction of nicotine analogue-containing oral pouch products in the United States
13
Toxicology Letters. Emerging nicotine analog 6-methyl nicotine increases reactive oxygen species in aerosols and cytotoxicity in human bronchial epithelial cells